tradingkey.logo

Oryzon Submits Phase III Trial Protocol For BPD Drug Vafidemstat To FDA

ReutersJun 23, 2025 6:15 AM

- Oryzon Genomics SA ORY.MC:

  • SUBMITS TO FDA CLINICAL TRIAL PROTOCOL FOR ITS PHASE III PORTICO-2 TRIAL OF VAFIDEMSTAT IN BORDERLINE PERSONALITY DISORDER (BPD) PATIENTS

  • PORTICO-2 TO EMPLOY TWO CLINICAL OUTCOME MEASURES FOR AGGRESSION AS PRIMARY ENDPOINT

  • TO EMPLOY OVERT AGGRESSION SCALE-MODIFIED (OAS-M) AS KEY SECONDARY ENDPOINT

  • ADDITIONAL SECONDARY ENDPOINTS TO EVALUATE BROADER CLINICAL IMPROVEMENTS IN BPD SYMPTOMATOLOGY AND LIFE QUALITY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI